



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Hauptmann *et al.*

Serial No. 08/249,671

Filed: May 26, 1994

For: *Process for Preparing and  
Purifying Alpha-Interferon*

Art Unit: To Be Assigned

Examiner: To Be Assigned

Atty Docket: 0652.1350000/RWE

#11  
B9J.  
2/29/96

### *Information Disclosure Statement*

Honorable Commissioner of  
Patents and Trademarks  
Washington, DC 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to the Applicants and/or their attorney in compliance with the requirements of 37 C.F.R. § 1.56. Copies of the documents are also being submitted herewith.

In accordance with 37 C.F.R. §1.98(a)(3), Applicants' undersigned representative submits the following concise explanation of the relevance of the non-English language document cited in the accompanying Form PTO-1449:

Reference AL1, European Patent EP 0 115 613 in German language, discloses the construction of a plasmid for the cytoplasmic, inducible expression of eukaryotic genes, esp. interferons, in prokaryotes under the control of the *trp*-promoter of *Serratia marcescens*.

Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application.

This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application are respectfully requested.

It is believed that no fees are due for consideration of this Information Disclosure Statement. Any fees which may be due may be debited to our Deposit Account 19-0036. A duplicate copy of this statement is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX



Robert W. Esmond  
Attorney for Applicants  
Registration No. 32,893

Date: Nov. 14, 1994

1100 New York Avenue, Suite 600  
Washington, D.C. 20005  
(202) 371-2600